Our Publications

Haberman Associates’ publications are designed to help you understand and act on the ever-changing science, technology, market, and strategic issues that affect the life science industry. They also help you assess leading companies and their products and technologies.

Our publications include in-depth research and analysis in:

  • Business strategy in the pharmaceutical, biotechnology, and life science industry
  • R&D strategy
  • Therapeutic area and pipeline strategy
  • Technology assessment

We apply similar types of research and analysis as in our publications to our consulting engagements. However, our consulting engagements focus on your company’s specific issues, and on developing executable recommendations for action in collaboration with you and your colleagues.

Organizations that publish our books and reports include Cambridge Healthtech Institute, Decision Resources, Informa (the parent company of Datamonitor, Scrip, Clinica, and PharmaProjects) and Emirates Center for Strategic Studies and Research (ECSSR).

We also produce articles that have appeared in such leading publications as Genetic Engineering & Biotechnology News, Pharma DD, and PharmaWeek. Please see our published articles page for examples.

For information on our recent major publications, or to order them, please click on the following links:

Gene Therapy: Moving Toward Commercialization. November 6, 2015. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.

Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies. September 9, 2014. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.

Advances in the Discovery of Protein-Protein Interaction Modulators. April 13, 2012.  Allan B. Haberman, Ph.D. Published by Informa/Scrip Insights.

Multitargeted Therapies: Promiscuous Drugs and Combination Therapies. June 1, 2011. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.

RNAi Therapeutics: Second Generation Candidates Build Momentum. November 4, 2010. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.

Animal Models for Therapeutic Strategies. March 5, 2010. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.

Approaches to Reducing Phase II Attrition. May 5, 2009. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.

Obesity Drug Pipeline: Developing Therapies for a Complex Disease. September 18, 2008. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.

Blood-Brain Barrier: Bridging Options for Drug Discovery and Development. May 9, 2008. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.

Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D. April 27, 2007. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.

“Biotechnology and the Future of the Pharmaceutical Industry”. Allan B. Haberman, Ph.D. In Biotechnology and the Future of Society: Challenges and Opportunities, Emirates Center for Strategic Studies and Research (ESCCR), distributed by I.B. Tauris, June 2004.

Available from the following sources:

Amazon.com

Barnes & Noble